NCT07766876Not yet recruiting
Cancer Ratio and Cancer Ratio Plus in Malignant and Tuberculous Pleural Effusions
Role of Cancer Ratio and Cancer Ratio Plus in the Differentiation Between Malignant and Tuberculous Pleural Effusions .
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
This prospective observational analytical study aims to assess the diagnostic value of Cancer Ratio and Cancer Ratio Plus in differentiating malignant pleural effusion from tuberculous pleural effusion. Adult patients with confirmed malignant or tuberculous pleural effusion will be recruited from the Chest Diseases Department, Sohag University Hospitals. Clinical, laboratory, and radiological data will be collected, and the diagnostic performance of both markers will be evaluated.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 2 Aug 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Sohag University
- NCT number
- NCT07766876
What you commit to
- Study type: Observational
- Planned participants: 120
- From 1 Sept 2026 to the primary completion date, 31 Aug 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior pleural interventions affecting fluid analysis
Other illness
- Patients with mixed etiology effusions (e.g., malignancy with infection)
Lab values
- Incomplete clinical or laboratory data
Who the study is looking for
- Adult patients (≥18 years)
- Patients with Malignant or tuberculous pleural effusion
- Availability of complete pleural fluid analysis including lymphocyte percentage ,pleural fluid ADA, and Serum LDH level
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.